Is Amgen Stock a Buy Now? [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
It has dealt with some issues lately, especially subpar financial results that have disappointed investors. Though Amgen remains one of the world's largest and most prominent drugmakers, its status alone isn't enough to make the stock a buy. Let's look deeper into what's going on with the business to determine whether it is worth buying its shares today. Can top-line growth bounce back? Last year, Amgen's total revenue increased by 7% year over year to $28.2 billion. While that's a decent performance for a biotech giant , some of that growth was due to the company's acquisition of Horizon Therapeutics for about $28 billion. The acquisition closed in early October but had time to contribute $954 million to Amgen's sales. Excluding that figure, Amgen's total revenue rose by 3.5% year over year, which isn't particularly impressive. Amgen has been dealing with competition for some of its medicines. The key will be to develop newer drugs. Amgen is working on that goal, including in
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY [Yahoo! Finance]Yahoo! Finance
- AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCYPR Newswire
- Biologic Therapeutics Drugs Market Size Projections Exhibit a CAGR of 12.2%%, Likely to Attain a Value of USD 1485.0 Billion by 2033 [Yahoo! Finance]Yahoo! Finance
- Microbial Products Market to Gain $286.53 Billion, by 2033 with 6% CAGR: States The Brainy Insights [Yahoo! Finance]Yahoo! Finance
- Why Amgen (AMGN) Outpaced the Stock Market Today [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 2/6/24 - Beat
AMGN
Sec Filings
- 4/26/24 - Form DEFA14A
- 4/17/24 - Form DEFA14A
- 4/17/24 - Form DEF
- AMGN's page on the SEC website